DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR)) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that MediMedia Managed Markets, an
ICON company, has received two gold industry awards in recognition of
innovative customer solutions.
MediMedia was awarded gold for the Best Use of Data Analytics at the 2017
Medical Marketing & Media (MM&M) Healthcare Awards. The
award recognised MediMedia's work on a stakeholder mapping and
segmentation project for a pharma customer, which involved mapping
hospitals to health systems, integrated delivery networks, group
purchasing organisations and accountable care organisations (ACOs).
MediMedia developed a fully integrated data ecosystem, including data
from 17 sources, that provided visibility across all customer types and
standardised performance measurement and reporting. The analysis and
supporting data ultimately helped to refine brand market access
strategy; revise sales alignment; and develop resources for
underperforming segments. Results included expanded inpatient formulary
coverage and improved utilisation rates with both system-affiliated and
ACO-affiliated consumers.
MediMedia also won gold in the Digital Media Mobile App category at the 2017
MarCom Awards, a global awards programme that honours excellence in
marketing and communication. MediMedia was a winner for developing a
Local Care Center Finder App for Otsuka America Pharmaceutical Inc. The
app, which is part of Otsuka's
ASSURE Program™, helps patients find alternate locations, such as
retail pharmacies and infusion centers, where they can receive their
prescribed injection from a licensed healthcare professional.
In addition to the two gold awards, Jodie McVan, Head Creative Services,
Global Access, Commercialisation and Communications, has also been
selected as a finalist in the 2017
Stevie Awards for Women in Business. More than 1,500 entries were
submitted in 2017 and Jodie was selected as a finalist in the Woman of
the Year - Advertising, Marketing & Public Relations category. Winners
will be announced at a ceremony in New York on 14 November.
Commenting on the awards, Ramita Tandon, EVP, ICON Commercialisation &
Outcomes, said: "We are honoured to be recognised as the industry's
best for mapping key stakeholders to support Market Access strategies
and improving product utilisation. ICON provides the real world
evidence-based expertise, insights, and tools to leverage our deeper
understanding of patient experiences and priorities, while accelerating
market access for products that are truly aligned to patient, payer, and
provider demands."
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees.
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171116005080/en/
ICON Press Office Enquiries
Weber Shandwick
Olivia
Pimenta
Email: LDNWSWICONClinical@corp.ipgnetwork.com
Source: ICON plc
News Provided by Acquire Media
